1Custodio A,Mendez M,Provencio M.Targeted therapies for advanced non-small-cell lung cancer:current status and future implications.Cancer Treat Rev,2012,38(1):36-53.
2Mendelsohn J.Blockade of receptors for growth factors:an anticancer therapy--the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture.Clin Cancer Res,2000,6(3):747-753.
3Ciardiello F,Caputo R,Bianco R,et al.Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa),a selective epidermal growth factor receptor tyrosine kinase inhibitor.Clin Cancer Res,2001,7(5):1459-1465.
4Park K,Goto K.A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer.Curr Med Res Opin,2006,22(3):561-573.
7Lynch TJ,Bell DW,Sordella R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.N Engl J Med,2004,350(21):2129-2139.
8Paez JG,Janne PA,Lee JC,et al.EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy.Science,2004,304(5676):1497-1500.
9Thatcher N,Chang A,Parikh P,et al.Gefitinib plus best supportive care in previously treated patients with refractory advanced nonsmall-cell lung cancer:Results from a randomised,placebocontrolled,multicentre study (Iressa Survival Evaluation in Lung Cancer).Lancet,2005,366(9496):1527-1537.
10Wataya H,Okamoto T,Maruyama R,et al.Prognostic factors in previously treated non-small-cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib.Lung Cancer,2009,64(3):341-345.
1Curran WJ Jr,Panlus R,Lanqer CJ. Sequential vs concurrent chemoradi- ation for stage III non -small cell lung cancer randomized phase II1 trial RTOG 9401[J]. J Natl Cancer Inst,2011,103(19):1452-1460.
2Oster JP, Zalcman G, Quoix E, ot al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in eldCrlypatients with advanced non small cell lung cance: IFCT -0501randomised,phase 3 trial[J]. Lancet, 2011 (378 ): 1079-1088.
3Kuiper JL,Heideman DA,Thunnissen E,et al.Incidence of T790M mutation in(sequential)rebiopsies in EGFR-mutated NSCLCpatients[J].Lung Cancer,2014.pii:S0169-5002(14)00137-138.
4Zimmermann S,Dziadziuszko R,Peters S.Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases[J].Cancer Treat Rev,2014,40(6):716-722.
5Wickersham KE,Happ MB,Bender CM,et al.Surviving with lung cancer:medication-taking and oral targeted therapy[J].Geriatr Nurs,2014,35(2 Suppl):S49-56.
6Li X,Wang H,Lin W,et al.Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non-small-cell lung cancer:a meta-analysis of 14randomized controlled trials[J].Curr Med Res Opin,2014,30(11):2295-2304.
7Domvri K,Zarogoulidis P,Darwiche K,et al.Molecular Targeted Drugs and Biomarkers in NSCLC,the Evolving Role of Individualized Therapy[J].J Cancer,2013,4(9):736-754.
8Yang L,Parkin DM,Ferlay J,et al.Estimates of cancer incidence in China for 2000 and projections for 2005[J].Cancer Epidemiol Biomarkers Prev,2005,14(1):243-250.
9Martinez P,Martinez-Marti A,Navarro A,et al.Molecular targeted therapy for early-stage non-small-cell lung cancer:Will it increase the cure rate[J].Lung Cancer,2014,84(2):97-100.
10Johnson ML,Patel JD.Chemotherapy and targeted therapeutics as maintenance of response in advanced non-small cell lung cancer[J].Semin Oncol,2014,41(1):93-100.
